* Xeris Biopharma Holdings Inc reported a quarterly adjusted loss of 11 cents per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -9 cents. The mean expectation of six analysts for the quarter was for a loss of 9 cents per share. Wall Street expected results to range from -10 cents to -6 cents per share.
* Revenue rose 12.3% to $54.27 million from a year ago; analysts expected $51.43 million.
* Xeris Biopharma Holdings Inc's reported EPS for the quarter was a loss of 11 cents.
* The company reported a quarterly loss of $15.74 million.
* Xeris Biopharma Holdings Inc shares had risen by 17.9% this quarter and gained 43.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 5.9% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Xeris Biopharma Holdings Inc is $5.00 This summary was machine generated from LSEG data November 8 at 04:24 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.09 -0.11 Missed
Jun. 30 2024 -0.11 -0.10 Beat
Mar. 31 2024 -0.14
Dec. 31 2023 -0.10 -0.10 Met
Comments